SURPASS-4, a multicenter open-label RCT comparing treatment with tirzepatide and insulin glargine in T2D patients at increased CV risk for a median of 85 weeks, was the only study in the SURPASS program to include the change from baseline in eGFR and UACR and occurrence of eGFR decline of at least 40%, renal death, progression to end-stage kidney disease or new-onset MA among the prespecified analyses [48]
$50 for you, and $50 for your friend
(PubMed) However, while some small studies report mild pigment/lightening changes with glutathione (oral or topical), the clinical evidence for long-term, safe, and effective skin-whitening via IV glutathione is weak or absent
Press gently with gauze after injecting, but dont rub the area
Headaches may recur briefly after dose increases but typically resolve with continued use and supportive measures like adequate hydration